Quintrio
Home

PHARMACEUTICAL PREPARATIONS

DiaMedica Therapeutics Inc. Common Stock

DMAC

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Last trade $8.14
Day change -$0.19 (-2.28%)
Day range $7.90 – $8.80
Volume 129,120
Market cap $449M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$449.47M
Price / earnings
—
Price / book
11.72×
Price / sales
—
EV / sales
—
EV / EBITDA
-11.34×

Profitability

Earnings per share
-$0.70
Return on assets
-83.39%
Return on equity
-97.88%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.72×
Quick ratio
6.72×
Cash ratio
0.78×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$31.54M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DMAC, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.35M$2.5M$2.51M$2.6M$2.19M$2.49M$1.95M$1.9M
Research and development$8.15M$7.99M$6.7M$6.44M$5.82M$5.66M$6.47M$4.98M
Total operating expenses$10.5M$10.48M$9.21M$9.03M$8.01M$8.14M$8.42M$6.88M
Operating income-$10.5M-$10.48M-$9.21M-$9.03M-$8.01M-$8.14M-$8.42M-$6.88M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$10.13M-$10.04M-$8.73M-$8.61M-$7.69M-$7.7M-$7.89M-$6.27M
Income taxes$7K$7K$10K$6K$6K$6K$9K$7K
Net income-$10.14M-$10.04M-$8.74M-$8.62M-$7.7M-$7.71M-$7.9M-$6.27M
Net income attributable to common shareholders-$10.15M-$10.04M-$8.71M-$8.62M-$7.72M-$7.71M-$7.88M-$6.27M
EBITDA-$10.49M-$10.47M-$9.2M-$9.02M-$8M-$8.13M-$8.41M-$6.87M
Basic earnings per share-$0.19-$0.19-$0.17-$0.17-$0.18-$0.18-$0.18-$0.15
Diluted earnings per share-$0.19-$0.19-$0.17-$0.17-$0.18-$0.18-$0.18-$0.15

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight

The acute ischemic stroke market is expected to grow significantly through 2036, driven by increased symptom awareness, advances in acute stroke care, and a robust pipeline of innovative therapies. Key candidates in development include lenzocimab, DM199, milvexian, and BB-031. The US accounts for the largest market share, with approximately 1.8 million incident cases across the 7MM in 2025. Recent developments include FDA approval of tenecteplase in March 2025 and encouraging Phase 2 results for LT3001.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.